Research and Markets: Global Generics Industry Report Estimates That the Global Generics Market Will Sustain a CAGR of 14% During the Period 2008-12

DUBLIN--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/research/991700/global_generics_in) has
announced the addition of the "Global Generics Industry Report" report to their
offering.

The global generics market was valued at US$106.12 billion in 2008, registering
a growth of 12.56% over the previous year, which is five times that of patented
drugs. Cygnus estimates that the global generics market will sustain a CAGR of
14% during the period, 2008-12. Patent expiries of blockbuster drugs and
increasing healthcare expenditure will continue to drive the growth of the
industry. The major generic firms will become more dominant with further
acquisitions in the future.

Scope of the Report:

* Get a global generics market overview with various patent challenges, mergers
and acquisitions and regional market overview (North America, Europe and Asia
Pacific) along with growth drivers of the industry are discussed to provide a
broad global scenario of the market.
* The industry faces several challenges, which are discussed in Issues and
Challenges chapter.
* The R&D expenditure of global generics companies has been discussed
separately, followed by regulations of the industry.
* Ten leading industry players are discussed in Major Players chapter discussing
their Business Profile, Financial Profile, Key Strategies, Outlook followed by
critical success factors.
* Another important topic i.e. key patent expiries during 2008-12 has been
discussed along with the future outlook of the industry.

Reasons to Buy

* Provides insight into the key concepts of Global Generics in a comprehensive
manner
* Useful to pharma industry experts, global investors and generics companies.
* Prepares students of Pharma Courses to face the industry confidently
* Can assess the industry status broadly by Financial institutes, offering term
loans to generic pharma companies

Key Topics Covered:

EXECUTIVE SUMMARY

HIGHLIGHTS

MARKET OVERVIEW

* Global generics market
* Growth rate comparison
* Geographical segmentation
* Ethical Vs. OTC generics
* Top 20 products in the US
* Major generic companies

INDUSTRY TREND

* Mergers and Acquisitions
* Patent challenges
* Regulatory changes
* New Distribution Models
* Centralised contracting and increasing role of payers

MAJOR MARKETS

* North America
* Europe
* Asia Pacific

GROWTH DRIVERS

* Cost advantage
* Increasing patent expiries
* Rising healthcare expenditure
* Greater M&A activities
* Shifting disease pattern
* Changing age structure of the global population

ISSUES AND CHALLENGES

* Authorized generics
* Patent extension strategies
* Price erosion leads to intense competition
* Litigation and legal aspects
* Competition from low cost manufacturers
* More branded companies in generic competition

RESEARCH AND DEVELOPMENT

* R&D spending by major generic companies
* Areas of R&D spend

REGULATIONS

* Regulatory aspects in the US
* Regulatory aspects in Europe
* Regulatory aspects in Japan
* International agreements on IPR protection

MAJOR PLAYERS

CRITICAL SUCCESS FACTORS

* Biogenerics
* Outsourcing
* Venturing into "difficult to make" generics
* Mergers and Acquisitions
* Investments in R&D
* Identifying the right patents to challenge
* Striking alliances

KEY PATENT EXPIRIES - 2008-12

Companies Mentioned:

* Teva Pharmaceutical Industries Ltd.
* Sandoz
* Watson Pharmaceuticals
* Mylan Inc.
* STADA
* Pliva
* Daiichi Sankyo
* Cipla Ltd
* Actavis
* Dr. Reddy's Laboratories Ltd

For more information visit
http://www.researchandmarkets.com/research/991700/global_generics_in

Laura Wood
Senior Manager
press@researchandmarkets.com
Fax from USA: 646-607-1907
Fax from rest of the world: +353-1-481-1716

Copyright Business Wire 2009